BiotechTube

recombinant human growth hormone

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Abdominal Obesity

Conditions

Abdominal Obesity, Metabolic Syndrome, Obesity

Trial Timeline

Jan 1, 1999 → May 1, 2005

NCT ID
NCT00781547

About recombinant human growth hormone

recombinant human growth hormone is a phase 3 stage product being developed by Pfizer for Abdominal Obesity. The current trial status is completed. This product is registered under clinical trial identifier NCT00781547. Target conditions include Abdominal Obesity, Metabolic Syndrome, Obesity.

What happened to similar drugs?

6 of 20 similar drugs in Abdominal Obesity were approved

Approved (6) Terminated (1) Active (14)
✅MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazoleMerckApproved
✅Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks + Placebo first followed by open label pregabalinPfizerApproved
✅Tigecycline + Imipenem/cilastatinPfizerApproved
✅tigecyclinePfizerApproved
✅Fibrinogen concentrate + Fresh Frozen PlasmaCSLApproved
✅Sevoflurane + propofol + remifentanilBaxterApproved
🔄PD-1 Inhibitors + Irinotecan + Capecitabine tabletsJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00781547Phase 3Completed

Competing Products

20 competing products in Abdominal Obesity

See all competitors
ProductCompanyStageHype Score
PD-1 Inhibitors + Irinotecan + Capecitabine tabletsJiangsu Hengrui MedicinePhase 3
36
HR021618 + PlaceboJiangsu Hengrui MedicinePhase 2
35
Ticagrelor + PlaceboAstraZenecaPhase 2
35
Relebactam 250 mg + Relebactam 125 mg + Imipenem/cilastatin + Matching placebo to relebactamMerckPhase 2
35
Ceftolozane/Tazobactam + Metronidazole + Meropenem + PlaceboMerckPhase 3
40
MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) + metronidazole 500 mgMerckPhase 3
40
CXA-201 and metronidazole + MeropenemMerckPhase 3
40
Imipenem+Cilastatin/RelebactamMerckPhase 3
40
CXA-101/ tazobactam and metronidazole + meropenem plus saline placeboMerckPhase 2
35
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo for MetronidazoleMerckPhase 2
35
Metformin Glucophage 500mg (IR) tablets M90 + Placebo Oral TabletMerckPhase 2/3
42
Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks + MK0826, /Duration of Treatment : 8 Weeks + Comparator: metronidazole / Duration of Treatment: 8 WeeksMerckPhase 3
40
MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazoleMerckApproved
43
MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 WeeksMerckPhase 3
40
LYS228 + Standard of care therapyNovartisPhase 2
27
ACZ885 + PlaceboNovartisPhase 2
27
Evolocumab + PlaceboAmgenPhase 1
36
tigecyclinePfizerPhase 3
40
Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks + Placebo first followed by open label pregabalinPfizerApproved
35
Ceftazidime-avibactam + metronidazole + MeropenemPfizerPhase 3
40